Featured News

Does living with celiac disease impact your daily life? We need your help to advance celiac disease research and test an investigational medication.  

Is celiac disease holding you back? If so, consider joining the FB102-301 study for people who have celiac disease who are currently on a gluten-free diet. The phase 2 FB102-301 study is researching a potential new…

Woodland Hills, CA — September 4, 2025 — The Celiac Disease Foundation today announced the launch of its Clinical Trials Site Advisory Council, a global panel of academic researchers, principal…

New research from Tampere University in Finland shows exciting progress in a new drug for celiac disease. This drug, ZED1227 could be used alongside a gluten-free diet to help manage…

The Celiac Disease Foundation is committed to accelerating research aimed at finding potential treatments and cures for celiac disease beyond the gluten-free diet. In order to do this, we need…

A new international study published in the journal Gastroenterology sheds light on the extensive economic burden of celiac disease. In addition to the cost of gluten-free  foods, the authors address…

Newly released data from Chugai Pharmaceuticals shows their drug candidate DONQ52 potently blocks gluten-specific t-cells and is ready for continued development. So, what does this mean for the celiac disease community?

The Celiac Disease Foundation is pleased to share important research and clinical trial news from Anokion, a biotechnology company evaluating a treatment for celiac disease. Using our iQualifyCeliac screening platform,…

Joining research studies and clinical trials is the only way to help scientists better understand this autoimmune disease and ultimately find a cure for celiac disease. This spring, I joined one of those important trials, funded by the Foundation, to help researchers with the development of a revolutionary new screening tool for celiac disease.

The Celiac Disease Foundation, a trusted partner in optimizing patient recruitment and retention, announces the launch of its iRecruitCeliac platform, which brings together solutions to accelerate enrollment in clinical trials for celiac disease and comorbid conditions.